医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

R-Tech Ueno: Notice of Revisions of Dividend Forecast

2014年02月14日 PM04:10
このエントリーをはてなブックマークに追加


 

TOKYO

R-Tech Ueno, Ltd. (JASDAQ:4573):

A resolution was passed during the Board of Directors’ Meeting held on February 12, 2014 to revise our dividend per share forecast as described below.

1. Reasons for the revisions made to the dividend forecast

We consider the return of profits to shareholders to be one of our important main issues. We will continue to deliver steady dividend distributions to our shareholders while considering future business performance.
In line with this policy and overall consideration of the current business performance and financial conditions, we have increased the expected dividend for the fiscal year ending March 2014 by 5 yen from 20 yen to 25 yen per share.

2. Revisions to the Dividend Forecast

(1) Dividend forecast for the fiscal year ending March 2014

 

  Annual dividend
End of 1st quarter   End of 2nd quarter   End of 3rd quarter   Year-end   Total
Yen Yen Yen Yen Yen
Previous forecast

20.00 20.00
Revised forecast

25.00 25.00
Actual results for the current fiscal year

   

(Reference)
Actual results
(Fiscal year ended March 2013)

 

 

 

  15.00   15.00
 
(Note)   We conducted a 200 for 1 stock split on July 1, 2013. Subsequently, we show the value of dividends for FY3/13 based upon an assumption that the stock split was performed at the start of the previous fiscal year. The dividend payment would be JPY3,000 per share if the effect of the stock split is excluded.
 

About R-Tech Ueno, Ltd.

R-Tech Ueno is a bio venture company established in September 1989 for the purpose of R&D and marketing of drugs. Under the leadership of the CEO, also a medical doctor, the company is developing new drugs on the theme “Physician-Oriented New Drug Innovation”, targeting ophthalmologic and dermatologic diseases that previously had no effective therapeutic agent.

We aim at becoming a “global pharmaceutical company specializing in specific fields (ophthalmology and dermatology) and developing and selling pharmaceutical products through the eyes of doctors.” We are promoting the development of new drugs for unmet medical needs for which the government provides recommendations and assistance, orphan drugs and the drugs in the field of anti-aging (lifestyle drugs).

CONTACT

R-Tech Ueno, Ltd.
Koji Nakamura, +81-3-3596-8011
Director
Business
Management Department
info@rtueno.co.jp

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • CANbridge Pharmaceutical and WuXi Biologics Enter into Strategic Partnership for Rare Disease Therapeutics
  • 武田呈报3期ALTA-1L试验结果,显示在晚期ALK+非小细胞肺癌一线治疗中,ALUNBRIG® (brigatinib)的颅内有效性优于克唑替尼
  • Philip Morris International Launches Next Generation of IQOS, the World’s Leading Heated Tobacco Product
  • PotNetwork Holdings, Inc.第三季度业绩创纪录,营收超过610万美元
  • ポットネットワーク・ホールディングスが610万ドルを超える収益で過去最高の第3四半期を終える